Renal FailureNCT00808561
Randomized Fistula Study
A study testing Group 1: Alternative Fistula and Group 2: Forearm AV Graft in people with Renal Failure, run by University of Pittsburgh at 1 site in United States.
Trial summary
The primary objective of this study is to compare two treatment strategies for establishing dialysis access in patients with unsuitable forearm veins for the standard forearm primary radio-cephalic arteriovenous fistula also known as the Brescia-Cimino fistula. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Renal Failure
- What is being tested?
- Group 1: Alternative Fistula and Group 2: Forearm AV Graft
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 6 participants
- Where
- 1 siteUnited States
- Study dates
- Dec 2008to Jan 2013
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- To participate in this study, the subject MUST have all of the following for inclusion in the study:
- The subject must be > 18 years of age, male or female
- Subject requires creation of dialysis access secondary to ESRD in the opinion of the referring nephrologist
- Target arm may have a failed radiocephalic fistula
- Contralateral failed or failing access may exist
- The subject must sign a written informed consent, prior to the procedure, using a form that is approved by the local Institutional Review Board.
Who cannot join
- To participate in this study, the subject may NOT HAVE any of the following at enrollment to the study:
- Target arm has existing forearm AV graft, either functional or non-functional
- Target arm has existing fistula, either functional or non-functional, other than a radio-cephalic at the wrist
- Target arm has documented subclavian vein occlusion
- Target arm has obviously suitable cephalic vein and radial artery for a primary radiocephalic fistula
- Target arm has no superficial veins existing as options for primary access. If so, a second surgeon will review the ultrasound to confirm
Show all 10Show fewer
- Active local or systemic infection at the time of surgery
- Known hypercoagulable state (e.g., antithrombin III deficiency, antiphospholipid or anticardiolipin antibodies, Factor IV Leiden, circulating lupus anticoagulant, history of heparin-induced thrombocytopenia, Protein C or S deficiency, prothrombin mutation or a history of recurrent deep venous thrombosis and/or pulmonary embolism)
- Disseminated malignancy or other terminal condition where subject is expected to live less than 6 months.
- Previous randomization in this trial
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15232
About this study
Official title: Prospective Randomized Trial of Fistula vs. Forearm AV Graft in Patients With Poor Venous Access; Protocol #3, Version 1
The primary objective of this study is to compare two treatment strategies for establishing dialysis access in patients with unsuitable forearm veins for the standard forearm primary radio-cephalic arteriovenous fistula also known as the Brescia-Cimino fistula.
Read the detailed description
BACKGROUND AND SIGNIFICANCE:
Among patients with end stage renal disease (ESRD) who require hemodialysis, the maintenance of an adequate vascular access is of critical importance. As the overall population in the U.S. ages, every year a greater number of patients are being maintained on hemodialysis with an estimated Medicare expenditure in excess of 1.25 billion dollars per year.1 The complications related to dialysis access are a major determinant of patient outcomes, including morbidity and mortality, and between 16-25% of hospital admissions for dialysis patients in the U.S. are related to dialysis access complications with an estimated cost of 100 million dollars.2
For patients with ESRD requiring chronic hemodialysis, the autogenous Brescia-Cimino fistula is the consensus best choice for the creation of an AV access site for hemodialysis. This type of primary fistula uses the radial artery at the wrist and a suitable cephalic vein at the level of the wrist. The fistula typically matures in 6-8 weeks when the vein and artery are normal, and provides good flow rates with a minimal incidence of ischemia of the hand. Infection rates are extremely low and long term patency is excellent. The disadvantage is a low maturation rate when the vein has segments of fibrosis from previous IV sites or venipunctures which are common in the cephalic vein at the wrist. Difficulty with fistula maturation can lead to prolonged time with a tunneled dialysis catheter (TDC) while the patient undergoes a variety of procedures to correct the fistula and allow it to mature. Up to 40% of forearm primary Brescia-Cimino fistulas either fail to mature or occlude prior to use, and the incidence of failure of forearm fistulas is significantly higher in women compared to men. Infection rates with tunneled dialysis catheters are roughly 10 times that of fistulas or grafts; therefore, months or even years with TDCs, while fistulas mature, can have consequences. Infections are estimated to account for 14% of deaths in ESRD patients.3
In the absence of a suitable cephalic vein at the wrist or in case of poor maturation, the two main options exist. They are both acceptable in clinical practice and are chosen based on the particular clinical scenario and, to some extent, surgeon preference. The options include:
- ePTFE (polytetrafluoroethylene) bridge AV graft typically anastomosed in the proximal forearm to the radial or brachial artery and to an antecubital vein. The advantages include a quick maturation of 2-3 weeks, excellent flow rates and high technical success rates. Although secondary patency rates approach 80% at one year postoperatively, disadvantages include a more involved surgical procedure, a lower primary patency than a well functioning AV fistula, and higher revision and infection rates.4, 5
- Performing other autogenous AV fistulas which include various options such as brachiocephalic AV fistula, basilic or brachial vein transpositions or a variety of other strategies to maintain a primary access. The advantage would be to maintain an autogenous all venous access with less risk of infection and thrombosis. Some of these procedures, however, may involve an extensive dissection, a longer time for maturation, and the resulting fistula can be more difficult to use even if functioning well. Several procedures are also performed on occasion to aid in maturation before an AV fistula is actually available for access. In addition, a "steal" phenomenon is more common with proximal fistulas as the flow rates can be excessively high with low central resistance in the larger veins, leading to a decrease in blood flow to the hand. All of these factors often translate into prolonged central venous catheter placement (TDC) for dialysis, which has been associated with a high incidence of infection and central vein stenosis, or thrombosis.6
Because of the superior patency of primary fistulas, the Kidney Disease Outcomes Quality Initiative (K/DOQI) and the Fistula First initiative have articulated the advantages of fistulas vs. ePTFE bridge grafts for long-term dialysis access and recommended that at least 50% of patients in any region be on dialysis through a primary fistula.7 In addition, in 2006 K/DOQI set a target of 66% for prevalent fistulas by 2009.8 Many surgeons have also adopted a 100% autogenous policy because of these recommendations without a critical assessment of the potential downside of that policy.9 Others continue to use ePTFE preferentially when a cephalic vein is not available.
Although there is no doubt that in suitable patients a primary fistula is better than a prosthetic graft, there are no data to guide the best treatment strategy in the absence of a suitable forearm cephalic vein. Although K/DOQI encourages creation of primary fistulas, the multiple procedures required for fistula maturation and prolonged time with tunneled dialysis catheters, their complications may outweigh the complications of ePTFE grafts.10
- Conditions
- Renal Failure
- Being tested
- Group 1: Alternative Fistula, Group 2: Forearm AV Graft
- Medical subject headings
- Renal Insufficiency
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Group 1: Alternative FistulaOther
Performing other autogenous AV fistulas which include various options such as brachiocephalic AV fistula, basilic or brachial vein transpositions or a variety of other strategies to maintain a primary access. The advantage would be to maintain an autogenous all venous access with less risk of infection and thrombosis.
Group 2: Forearm AV GraftOther
- ePTFE (polytetrafluoroethylene) bridge AV graft typically anastomosed in the proximal forearm to the radial or brachial artery and to an antecubital vein. The advantages include a quick maturation of 2-3 weeks, excellent flow rates and high technical success rates. Although secondary patency rates approach 80% at one year postoperatively, disadvantages include a more involved surgical procedure, a lower primary patency than a well functioning AV fistula, and higher revision and infection rates.4, 5
| Study group | Role | What they receive |
|---|---|---|
| 1 Alternative Fistula | Active comparator | Not described Receives: Other: Group 1: Alternative Fistula |
| 2 Forearm AV Graft | Active comparator | Not described Receives: Other: Group 2: Forearm AV Graft |
What is being measured
The primary outcome is the main question the study is designed to answer.
The primary endpoint will be the rate of composite adverse events at one year with follow-up to 3 years. Data will be tabulated every 6 months.
Measured: 12 months
Secondary outcomes (6)
Secondary endpoints: Primary, assisted primary, and secondary patency at 1 and 3 years
Measured: 3 years
Death due to access-related illness
Measured: 3 years
Death due to any cause
Measured: 3 Years
New central venous stenosis or occlusion
Measured: 3 years
Steal syndrome
Measured: 3 years
Neuropathy
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Dec 2008 (estimated)
- Study startDec 2008
- Primary completionJan 2011
- Study completionJan 2013
Why it stopped: Slow enrollment due to multiple screen failures
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Renal FailureStudies of the same condition, open and under way.
- More trials run by University of PittsburghThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 6 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Pittsburgh
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Navyash Gupta, MD, Principal investigator, University of Pittsburgh Physicians
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00808561
- Sponsor's protocol ID
- Protocol #3, V1, Fistula
- Status last verified
- Mar 2016
- First submitted
- 12 Dec 2008
- Last updated
- 11 Mar 2016
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 11 Mar 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Randomized Trial of Fistula vs. Forearm AV Graft in Patients With Poor Venous Access; Protocol #3, Version 1
- ClinicalTrials.gov ID
- NCT00808561
- Acronym / sponsor ID
- Protocol #3, V1, Fistula
- Conditions
- Renal Failure
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Slow enrollment due to multiple screen failures
- Enrolment
- 6 participants (actual)
- Lead sponsor
- University of PittsburghUniversity, hospital or other
- Study start
- Dec 2008
- Primary completion
- Jan 2011 (actual)
- Study completion
- Jan 2013 (actual)
- First posted
- 16 Dec 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study is to compare two treatment strategies for establishing dialysis access in patients with unsuitable forearm veins for the standard forearm primary radio-cephalic arteriovenous fistula also known as the Brescia-Cimino fistula.
Detailed description
BACKGROUND AND SIGNIFICANCE:
Among patients with end stage renal disease (ESRD) who require hemodialysis, the maintenance of an adequate vascular access is of critical importance. As the overall population in the U.S. ages, every year a greater number of patients are being maintained on hemodialysis with an estimated Medicare expenditure in excess of 1.25 billion dollars per year.1 The complications related to dialysis access are a major determinant of patient outcomes, including morbidity and mortality, and between 16-25% of hospital admissions for dialysis patients in the U.S. are related to dialysis access complications with an estimated cost of 100 million dollars.2
For patients with ESRD requiring chronic hemodialysis, the autogenous Brescia-Cimino fistula is the consensus best choice for the creation of an AV access site for hemodialysis. This type of primary fistula uses the radial artery at the wrist and a suitable cephalic vein at the level of the wrist. The fistula typically matures in 6-8 weeks when the vein and artery are normal, and provides good flow rates with a minimal incidence of ischemia of the hand. Infection rates are extremely low and long term patency is excellent. The disadvantage is a low maturation rate when the vein has segments of fibrosis from previous IV sites or venipunctures which are common in the cephalic vein at the wrist. Difficulty with fistula maturation can lead to prolonged time with a tunneled dialysis catheter (TDC) while the patient undergoes a variety of procedures to correct the fistula and allow it to mature. Up to 40% of forearm primary Brescia-Cimino fistulas either fail to mature or occlude prior to use, and the incidence of failure of forearm fistulas is significantly higher in women compared to men. Infection rates with tunneled dialysis catheters are roughly 10 times that of fistulas or grafts; therefore, months or even years with TDCs, while fistulas mature, can have consequences. Infections are estimated to account for 14% of deaths in ESRD patients.3
In the absence of a suitable cephalic vein at the wrist or in case of poor maturation, the two main options exist. They are both acceptable in clinical practice and are chosen based on the particular clinical scenario and, to some extent, surgeon preference. The options include:
- ePTFE (polytetrafluoroethylene) bridge AV graft typically anastomosed in the proximal forearm to the radial or brachial artery and to an antecubital vein. The advantages include a quick maturation of 2-3 weeks, excellent flow rates and high technical success rates. Although secondary patency rates approach 80% at one year postoperatively, disadvantages include a more involved surgical procedure, a lower primary patency than a well functioning AV fistula, and higher revision and infection rates.4, 5
- Performing other autogenous AV fistulas which include various options such as brachiocephalic AV fistula, basilic or brachial vein transpositions or a variety of other strategies to maintain a primary access. The advantage would be to maintain an autogenous all venous access with less risk of infection and thrombosis. Some of these procedures, however, may involve an extensive dissection, a longer time for maturation, and the resulting fistula can be more difficult to use even if functioning well. Several procedures are also performed on occasion to aid in maturation before an AV fistula is actually available for access. In addition, a "steal" phenomenon is more common with proximal fistulas as the flow rates can be excessively high with low central resistance in the larger veins, leading to a decrease in blood flow to the hand. All of these factors often translate into prolonged central venous catheter placement (TDC) for dialysis, which has been associated with a high incidence of infection and central vein stenosis, or thrombosis.6
Because of the superior patency of primary fistulas, the Kidney Disease Outcomes Quality Initiative (K/DOQI) and the Fistula First initiative have articulated the advantages of fistulas vs. ePTFE bridge grafts for long-term dialysis access and recommended that at least 50% of patients in any region be on dialysis through a primary fistula.7 In addition, in 2006 K/DOQI set a target of 66% for prevalent fistulas by 2009.8 Many surgeons have also adopted a 100% autogenous policy because of these recommendations without a critical assessment of the potential downside of that policy.9 Others continue to use ePTFE preferentially when a cephalic vein is not available.
Although there is no doubt that in suitable patients a primary fistula is better than a prosthetic graft, there are no data to guide the best treatment strategy in the absence of a suitable forearm cephalic vein. Although K/DOQI encourages creation of primary fistulas, the multiple procedures required for fistula maturation and prolonged time with tunneled dialysis catheters, their complications may outweigh the complications of ePTFE grafts.10
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 Alternative Fistula | Active comparator | Other: Group 1: Alternative Fistula |
| 2 Forearm AV Graft | Active comparator | Other: Group 2: Forearm AV Graft |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- To participate in this study, the subject MUST have all of the following for inclusion in the study:
- The subject must be > 18 years of age, male or female
- Subject requires creation of dialysis access secondary to ESRD in the opinion of the referring nephrologist
- Target arm may have a failed radiocephalic fistula
- Contralateral failed or failing access may exist
Key exclusion criteria (10 listed)
- To participate in this study, the subject may NOT HAVE any of the following at enrollment to the study:
- Target arm has existing forearm AV graft, either functional or non-functional
- Target arm has existing fistula, either functional or non-functional, other than a radio-cephalic at the wrist
- Target arm has documented subclavian vein occlusion
- Target arm has obviously suitable cephalic vein and radial artery for a primary radiocephalic fistula
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Group 1: Alternative FistulaPerforming other autogenous AV fistulas which include various options such as brachiocephalic AV fistula, basilic or brachial vein transpositions or a variety of other strategies to maintain a primary access. The advantage would be to maintain an autogenous all venous access with less risk of infection and thrombosis. | Other | 1 Alternative Fistula |
| Group 2: Forearm AV Grafta) ePTFE (polytetrafluoroethylene) bridge AV graft typically anastomosed in the proximal forearm to the radial or brachial artery and to an antecubital vein. The advantages include a quick maturation of 2-3 weeks, excellent flow rates and high technical success rates. Although secondary patency rates approach 80% at one year postoperatively, disadvantages include a more involved surgical procedure, a lower primary patency than a well functioning AV fistula, and higher revision and infection rates.4, 5 | Other | 2 Forearm AV Graft |
Primary outcome
The primary endpoint will be the rate of composite adverse events at one year with follow-up to 3 years. Data will be tabulated every 6 months.
Time frame: 12 months
6 secondary outcomes
Secondary endpoints: Primary, assisted primary, and secondary patency at 1 and 3 years
Time frame: 3 years
Death due to access-related illness
Time frame: 3 years
Death due to any cause
Time frame: 3 Years
New central venous stenosis or occlusion
Time frame: 3 years
Steal syndrome
Time frame: 3 years
Neuropathy
Time frame: 3 years
Results and safety
The study was stopped early (reason given: Slow enrollment due to multiple screen failures). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Mar 2016.
Related trials for Renal Failure
Recruiting
Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula
End Stage Renal Disease
RecruitingObservational study
A Natural History Study of Metabolic Sizing in Health and Disease
Metabolic Disorders, Cancer
Active, not recruitingPhase 1/2
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Not yet recruiting
Manual Acupuncture for Intradialytic Nausea and Vomiting in Patients Undergoing Hemodialysis
Intradialytic Nausea and Vomiting, Chronic Kidney Disease
Not yet recruitingObservational study
Unmasking Diabetes in Dialysis With Continuous Glucose Monitoring
End Stage Kidney Disease (ESKD), Hyperglycaemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Navyash Gupta, MD principal investigator
University of Pittsburgh Physicians
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Group 1: Alternative Fistula and Group 2: Forearm AV Graft in people with Renal Failure, run by University of Pittsburgh at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 11 Mar 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Slow enrollment due to multiple screen failures). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The primary endpoint will be the rate of composite adverse events at one year with follow-up to 3 years. Data will be tabulated every 6 months. (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Mar 2016.